Klazien Matter‐Walstra

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

Klazien Matter‐Walstra, Matthias Schwenkglenks, Stefan Aebi et al. · Journal of Thoracic Oncology · 2016 · 89 citations

Medicine, Nivolumab Versus Docetaxel, Cost-effectiveness Analysis +1

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

Konstantin J. Dedes, Klazien Matter‐Walstra, Matthias Schwenkglenks et al. · European Journal of Cancer · 2009 · 76 citations

Breast Oncology, Oncology, Medicine +4

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Christoph Rochlitz, Martin Bigler, Roger von Moos et al. · BMC Cancer · 2016 · 46 citations · Full text

End-of-life costs of medical care for advanced stage cancer patients

Aleksandra Kovačević, Viktorija Dragojević-Simić, Nemanja Rančić et al. · Vojnosanitetski pregled · 2015 · 42 citations · Full text

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Klazien Matter‐Walstra, Dirk Klingbiel, Thomas D. Szucs et al. · PharmacoEconomics · 2014 · 41 citations

Translational Medicine, Oncology, Clinical Endpoint +7